Onconetix, Inc. (ONCO)
NASDAQ: ONCO · IEX Real-Time Price · USD
0.173
+0.016 (10.06%)
At close: Jul 2, 2024, 4:00 PM
0.162
-0.011 (-6.54%)
After-hours: Jul 2, 2024, 7:51 PM EDT
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Ralph Schiess Ph.D. |
Contact Details
Address: 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513-620-4101 |
| Website | onconetix.gcs-web.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 682160106 |
| ISIN Number | US09610B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ralph Schiess Ph.D. | Interim Chief Executive Officer and Chief Science Officer |
| Bruce Harmon | Chief Financial Officer |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Frank A. Jaeger M.A., M.B.A. | Senior Vice President of Marketing and Business Development |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Christian Bruhlmann | Chief Strategy Officer and GM of Europe |
| Dr. Donald L. Very Jr., Ph.D. | Senior Vice President of Commercial Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | EFFECT | Notice of Effectiveness |
| Jun 25, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 25, 2024 | PRER14A | Filing |
| Jun 14, 2024 | 8-K/A | [Amend] Current report |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 5, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2024 | PRER14A | Filing |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |